

Risk factors for adverse cardiovascular events in liver transplantation

Submission date 04/02/2025	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 06/02/2025	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 06/02/2025	Condition category Circulatory System	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Liver cirrhosis is a terminal and irreversible stage of chronic hepatic disease. The etiology is various and includes alcohol, infections, carcinoma, medicaments and toxins, immune disease, cholestasis, metabolic causes, sarcoidosis etc. Therapy in end-stage liver disease is liver transplantation. A cadaveric orthotopic transplantation liver graft is a liver transplant where the donor organ (the graft) is taken from a deceased person (cadaver) and placed in the recipient's body in the same anatomical position as their native liver, replacing it completely. The donor and recipient's factors influence the transplantation procedure and its outcome, affecting post-transplant morbidity and mortality. Liver transplantation poses a high risk for cardiovascular complications and cardiac death. It can reverse certain pathologic states induced by hepatic disease but it can also lead to acute decompensation and cardiac death. Current studies show different incidences of cardiovascular adverse events during and after liver transplantation, without connecting donor-recipient traits to these events. This study aims to find the incidence of adverse cardiovascular events during orthotopic liver transplantation and during early posttransplant time and to establish which factors, donor and recipient, contribute to these adverse events. Furthermore, the study will create a simple grading scale that allows us to predict the incidence of severe cardiovascular adverse events in this vulnerable group of patients.

Who can participate?

All patients aged 18 years old and over who were admitted to University Hospital Merkur, Zagreb, Croatia for liver transplants between 2013 and 2015

What does the study involve?

The medical records of patients who are admitted for liver transplantation are reviewed, including their charts during and after surgery. Information about the donors is obtained from Eurotransplant donor reports. Scoring systems will be used to model the study outcomes.

What are the possible benefits and risks of participating?

The overall benefit of the study is for further patients who will be undergoing liver transplantation in future. Since this is an observational, non-intervention retrospective chart review study, there is no risk for participants.

Where is the study run from?
University Hospital Merkur (Klinička bolnica Merkur)

When is the study starting and how long is it expected to run for?
January 2013 to July 2016

Who is funding the study?
Investigator initiated and funded

Who is the main contact?
Nataša Višković Filipčić, MD., natasa.viskovic-filipcic@agram-bolnica.hr, natashav7@gmail.com

Contact information

Type(s)

Public, Scientific, Principal Investigator

Contact name

Mrs Nataša Višković Filipčić

ORCID ID

<http://orcid.org/0009-0009-5804-3912>

Contact details

Školska 25
Velika Mlaka
Croatia
10408
+385 0913355998
natasa.viskovic-filipcic@agram-bolnica.hr

Type(s)

Public, Scientific, Principal Investigator

Contact name

Mrs Nataša Višković Filipčić

Contact details

Školska 25
Velika Mlaka
Croatia
10408
+385 0913355998
natashav7@gmail.com

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number**ClinicalTrials.gov number**

Nil known

Secondary identifying numbers

Nil known

Study information

Scientific Title

Risk factors associated with adverse cardiovascular events during orthotopic liver transplantation and during early posttransplant time

Acronym

ACV-OLT

Study objectives

The incidence of adverse cardiovascular events during orthotopic liver transplantation and early posttransplant time is less than 5%.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 01/12/2014, Ethics Committee of University Hospital Merkur (Zajčeva 19, Zagreb, 10000, Croatia; +385 1 2353 801; eticko.povjerenstvo@kb-merkur.hr), ref: 0311-13652

Study design

Single-center 3-year observational study

Primary study design

Observational

Secondary study design

Cohort study

Study setting(s)

Hospital, Medical and other records

Study type(s)

Prevention

Participant information sheet

No participant information sheet available

Health condition(s) or problem(s) studied

Adverse cardiovascular events in patients eligible for liver transplantation during the procedure itself and early posttransplant time

Interventions

Medical records of patients admitted for liver transplantation and their intraoperative and postoperative charts are examined. Donor data are acquired from Eurotransplant donor reports. Any subsequent scores are calculated according to official scoring systems (MELD, DRI).

Intervention Type

Procedure/Surgery

Primary outcome measure

To establish the incidence of adverse cardiovascular events in a group of patients with liver transplantation during the transplant procedure and early posttransplant time (30 days) measured using data collected from patient medical records at one time point

Secondary outcome measures

The following secondary outcome measures are evaluated measured using data collected from patient medical records at one time point:

1. Donor and recipient characteristics in a subgroup of patients with severe adverse cardiovascular events
2. The risk of adverse cardiovascular complications in the subgroup of patients with severe adverse cardiovascular events defined using a simple grading scale
3. To create a simple scale based on donor and recipient characteristics, used for risk assessment

Overall study start date

01/01/2013

Completion date

10/07/2016

Eligibility

Key inclusion criteria

1. Patients admitted and undergoing liver transplantation in UH Merkur, Zagreb, Croatia
2. 18 years of age and older

Participant type(s)

Patient

Age group

Mixed

Lower age limit

18 Years

Upper age limit

100 Years

Sex

Both

Target number of participants

Total final enrolment

291

Key exclusion criteria

1. Age less than 18 years
2. Liver re-transplantation
3. Acute liver failure
4. Living donor liver transplantation
5. Multiorgan transplantation

Date of first enrolment

10/08/2015

Date of final enrolment

10/07/2016

Locations

Countries of recruitment

Croatia

Study participating centre

University Hospital Merkur

Zajčeva ulica 19

Zagreb

Croatia

10000

Sponsor information

Organisation

Klinička bolnica Merkur

Sponsor details

Zajčeva 19

Zagreb

Croatia

10000

+385 1 2431 390

ravnateljstvo@kb-merkur.hr

Sponsor type

Hospital/treatment centre

Website

<https://www.kb-merkur.hr/>

ROR

<https://ror.org/01b6d9h22>

Funder(s)**Funder type**

Other

Funder Name

Investigator initiated and funded

Results and Publications**Publication and dissemination plan**

Planned publication in a peer-reviewed journal.

Intention to publish date

30/06/2025

Individual participant data (IPD) sharing plan

The dataset generated and/or analysed during the current study are not expected to be made available due to transplant laws and regulations

IPD sharing plan summary

Not expected to be made available